Zeneca Ltd. - परिणामों की खोज

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

tezspire

astrazeneca ab - tezepelumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

beyfortus

astrazeneca ab - nirsevimab - immunoseerumit ja immunoglobuliinit, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiset aineet - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

qtern

astra zeneca ab - saxagliptin dapagliflotsiini propaanidioli monohydraatti - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - diabeetilla käytettävät lääkkeet - qtern, kiinteä annos yhdistelmä saxagliptin ja dapagliflotsiinia, on tarkoitettu aikuisille 18-vuotiaat ja vanhemmat, joilla on tyypin 2 diabetes:parantaa sokeritasapainoa, kun metformiinin ja/tai sulfonyyliurean (su) ja yksi monocomponents ja qtern eivät tarjoa riittävää veren glukoositasapainoa,kun jo hoidettiin ilmainen yhdistelmä dapagliflotsiinin ja saxagliptin. (ks. kohdat 4. 2, 4. 4, 4. 5 ja 5. 1 käytettävissä olevien tietojen yhdistelmiä tutkittu.